This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2017 by Pfizer
Information provided by (Responsible Party):
Pfizer Identifier:
First received: July 11, 2006
Last updated: September 5, 2017
Last verified: September 2017
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes.

Condition Intervention Phase
Epilepsies, Partial Drug: Lyrica (pregabalin) Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Prospective Randomized 12-week Controlled Study Of Visual Field Change In Subjects With Partial Seizures Receiving Pregabalin Or Placebo

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Changes in vision from baseline to end of study assessed by the Humphrey Visual Field Analzyer. [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Visual acuity will be assessed at the baseline and end of the study. [ Time Frame: 3 months ]
  • Change in mean deviation score on the Humphrey Visual Field at baseline and end of the study. [ Time Frame: 3 months ]

Estimated Enrollment: 284
Actual Study Start Date: July 26, 2006
Estimated Study Completion Date: November 11, 2019
Estimated Primary Completion Date: November 11, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active
Active drug
Drug: Lyrica (pregabalin)
150 mg twice a day, oral administration
Placebo Comparator: Placebo
placebo comparator
Drug: placebo
Twice a day, oral administration


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Epilepsy partial seizure subjects.
  • Currently taking 1 to 3 antiepileptic drugs.

Exclusion Criteria:

  • Pre-existing eye diseases (glaucoma).
  • Insufficient response to pregabalin in the treatment of partial seizure, or patients currently receiving pregabalin treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00351611

Contact: Pfizer Call Center 1-800-718-1021

  Show 165 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00351611     History of Changes
Other Study ID Numbers: A0081096
2009-014269-25 ( EudraCT Number )
Study First Received: July 11, 2006
Last Updated: September 5, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Pfizer:
epilepsy partial seizure treatment with pregabalin or placebo
vision testing

Additional relevant MeSH terms:
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs processed this record on September 20, 2017